Skip to main content
Top
Published in:

03-01-2024 | Valsartan | Narrative Review

Clinician’s Approach to Advanced Statistical Methods: Win Ratios, Restricted Mean Survival Time, Responder Analyses, and Standardized Mean Differences

Authors: Melissa Lane, BSc Pharm, ACPR, ACPR2, Tyson Miao, BScPsyc, PharmD, ACPR, ACPR2, Ricky D. Turgeon, BSc Pharm, ACPR, PharmD

Published in: Journal of General Internal Medicine | Issue 7/2024

Login to get access

Abstract

Novel statistical methods have emerged in recent medical literature, which clinicians must understand to properly appraise and integrate evidence into their practice. Some of these key concepts include win ratios, restricted mean survival time, responder analyses, and standardized mean difference. This article offers guidance to busy clinicians on the comprehension and practical applicability of the results to patients. Win ratios provide an alternative method to analyze composite outcomes by prioritizing individual components of the composite; prioritization of the outcomes should be evidence-based, pre-specified, and patient-centered. Restricted mean survival time presents a method to analyze Kaplan–Meier curves when assumptions required for Cox proportional hazards analysis are not met. As it only considers outcomes that occur within a specific timeframe, the duration of follow-up must be appropriately defined and based on prior epidemiologic and mechanistic evidence. Researchers can analyze continuous outcomes with responder analyses, in which participants are dichotomized into “responders” or “non-responders.” While clinicians and patients may more easily grasp outcomes analyzed in this way, they should be aware of the loss of information and resulting imprecision, as well as potential to manipulate data presentation. When meta-analyzing continuous outcomes, point estimates can be converted to standardized mean differences to facilitate the combination of data utilizing various outcome measures. However, clinicians may find it challenging to grasp the clinical meaningfulness of a standardized mean difference, and may benefit from converting it to well-known outcomes. By providing the background knowledge of these statistical methods, along with practical applicability, benefits, and inevitable limitations, this article aims to provide clinicians with an approach to appraise the literature and apply the results in clinical practice.
Literature
1.
go back to reference Redfors B, Gregson J, Crowley A et al. The win ratio approach for composite endpoints: practical guidance based on previous experience. Eur Heart J. 2020;41(46):4391–9. Redfors B, Gregson J, Crowley A et al. The win ratio approach for composite endpoints: practical guidance based on previous experience. Eur Heart J. 2020;41(46):4391–9.
2.
go back to reference Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J. 2011;33(2):176–82. Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J. 2011;33(2):176–82.
3.
go back to reference Wentz RJ, Ward JH, Hernandez AF et al. Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure. J Am Coll Cardiol. 2023;82(1):1–12. Wentz RJ, Ward JH, Hernandez AF et al. Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure. J Am Coll Cardiol. 2023;82(1):1–12.
4.
go back to reference Biegus J, Voors AA, Collins SP et al. Impact of empagliflozin on decongestion in acute heart failure: the Empulse trial. Eur Heart J. 2022;44(1):41–50. Biegus J, Voors AA, Collins SP et al. Impact of empagliflozin on decongestion in acute heart failure: the Empulse trial. Eur Heart J. 2022;44(1):41–50.
5.
go back to reference Ferreira JP, Jhund PS, Duarte K et al. Use of the win ratio in cardiovascular trials. JACC Heart Fail. 2020;8(6):441–50. Ferreira JP, Jhund PS, Duarte K et al. Use of the win ratio in cardiovascular trials. JACC Heart Fail. 2020;8(6):441–50.
6.
go back to reference Ajufo E, Nayak A, Mehra MR. Fallacies of using the win ratio in cardiovascular trials. JACC Basic Transl Sci. 2023;8(6):720–7. Ajufo E, Nayak A, Mehra MR. Fallacies of using the win ratio in cardiovascular trials. JACC Basic Transl Sci. 2023;8(6):720–7.
7.
go back to reference Guimarães HP, Lopes RD, de Barros e Silva PGM et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med. 2020;383(22):2117–26. Guimarães HP, Lopes RD, de Barros e Silva PGM et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med. 2020;383(22):2117–26.
8.
go back to reference Gregson J, Sharples L, Stone GW, Burman C-F, Öhrn F, Pocock S. Nonproportional hazards for time-to-event outcomes in clinical trials. Journal of the American College of Cardiology. 2019;74(16):2102–12. Gregson J, Sharples L, Stone GW, Burman C-F, Öhrn F, Pocock S. Nonproportional hazards for time-to-event outcomes in clinical trials. Journal of the American College of Cardiology. 2019;74(16):2102–12.
9.
go back to reference Hasegawa T, Misawa S, Nakagawa S et al. Restricted mean survival time as a summary measure of time to event outcome. Pharmaceutical Statistics. 2020;19(4):436–53. Hasegawa T, Misawa S, Nakagawa S et al. Restricted mean survival time as a summary measure of time to event outcome. Pharmaceutical Statistics. 2020;19(4):436–53.
10.
go back to reference Kim DH, Uno H, Wei L-J. Restricted mean survival time as a measure to interpret clinical trial results. JAMA Cardiology. 2017;2(11):1179-80. Kim DH, Uno H, Wei L-J. Restricted mean survival time as a measure to interpret clinical trial results. JAMA Cardiology. 2017;2(11):1179-80.
11.
go back to reference Han K, Jung I. Restricted mean survival time for survival analysis: a quick guide for clinical researchers. Korean Journal of Radiology. 2022;23(5):495-99.CrossRefPubMedPubMedCentral Han K, Jung I. Restricted mean survival time for survival analysis: a quick guide for clinical researchers. Korean Journal of Radiology. 2022;23(5):495-99.CrossRefPubMedPubMedCentral
12.
go back to reference Connolly SJ, Karthikeyan G, Ntsekhe M et al. Rivaroxaban in rheumatic heart disease–associated atrial fibrillation. New England Journal of Medicine. 2022;387(11):978–88. Connolly SJ, Karthikeyan G, Ntsekhe M et al. Rivaroxaban in rheumatic heart disease–associated atrial fibrillation. New England Journal of Medicine. 2022;387(11):978–88.
13.
go back to reference Snapinn SM, Jiang Q. Responder analyses and the assessment of a clinically relevant treatment effect. Trials. 2007;8(1). Snapinn SM, Jiang Q. Responder analyses and the assessment of a clinically relevant treatment effect. Trials. 2007;8(1).
14.
go back to reference Cook CE, Bejarano G, Reneker J, Vigotsky AD, Riddle DL. Responder analyses: a methodological mess. J Orthop Sports Phys Ther. 2023;1–9. Cook CE, Bejarano G, Reneker J, Vigotsky AD, Riddle DL. Responder analyses: a methodological mess. J Orthop Sports Phys Ther. 2023;1–9.
15.
go back to reference Duru G, Fantino B. The clinical relevance of changes in the Montgomery–Asberg Depression rating scale using the minimum clinically important difference approach. Curr Med Res Opin. 2008;24(5):1329–35. Duru G, Fantino B. The clinical relevance of changes in the Montgomery–Asberg Depression rating scale using the minimum clinically important difference approach. Curr Med Res Opin. 2008;24(5):1329–35.
16.
go back to reference Dean RL, Hurducas C, Hawton K et al. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev. 2021;2021(11). Dean RL, Hurducas C, Hawton K et al. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev. 2021;2021(11).
17.
go back to reference Fedorov V, Mannino F, Zhang R. Consequences of dichotomization. Pharm Stat. 2009;8(1):50–61. Fedorov V, Mannino F, Zhang R. Consequences of dichotomization. Pharm Stat. 2009;8(1):50–61.
18.
go back to reference Murad MH, Wang Z, Chu H, Lin L. When continuous outcomes are measured using different scales: guide for meta-analysis and interpretation. BMJ. 2019; 364: k4817 Murad MH, Wang Z, Chu H, Lin L. When continuous outcomes are measured using different scales: guide for meta-analysis and interpretation. BMJ. 2019; 364: k4817
19.
go back to reference Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: L. Erlbaum Associates; 1988. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: L. Erlbaum Associates; 1988.
Metadata
Title
Clinician’s Approach to Advanced Statistical Methods: Win Ratios, Restricted Mean Survival Time, Responder Analyses, and Standardized Mean Differences
Authors
Melissa Lane, BSc Pharm, ACPR, ACPR2
Tyson Miao, BScPsyc, PharmD, ACPR, ACPR2
Ricky D. Turgeon, BSc Pharm, ACPR, PharmD
Publication date
03-01-2024
Publisher
Springer International Publishing
Published in
Journal of General Internal Medicine / Issue 7/2024
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-023-08582-w

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more